Review Article

Immunopathogenesis of Ocular Behçet’s Disease

Un Chul Park,¹ Tae Wan Kim,²,³ and Hyeong Gon Yu³,⁴

¹ Department of Ophthalmology, National Medical Center, 245 Euljiro, Jung-gu, Seoul 100-799, Republic of Korea
² Department of Ophthalmology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, No. 395 Shindaebang-2-dong, Dongjak-gu, Seoul 156-707, Republic of Korea
³ Department of Ophthalmology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 110-799, Republic of Korea
⁴ Sensory Organs Institute, Medical Research Center, Seoul National University, 103 Daehak-ro, Jongno-gu, Seoul 110-799, Republic of Korea

Correspondence should be addressed to Tae Wan Kim; twkim93@medimail.co.kr

Received 28 March 2014; Accepted 10 June 2014; Published 2 July 2014

Academic Editor: Ghislain Opdenakker

Copyright © 2014 Un Chul Park et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Behçet’s disease (BD) is a chronic recurrent systemic inflammatory disorder of unknown etiology characterized by oral and genital ulcerations, skin lesions, and uveitis. The ocular involvement of BD, or Behçet’s uveitis (BU), is characterized by panuveitis or posterior uveitis with occlusive retinal vasculitis and tends to be more recurrent and sight threatening than other endogenous autoimmune uveitides, despite aggressive immunosuppression. Although pathogenesis of BD is unclear, researches have revealed that immunological aberrations may be the cornerstone of BD development. General hypothesis of BD pathogenesis is that inflammatory response is initiated by infectious agents or autoantigens in patients with predisposing genetic factors and perpetuated by both innate and acquired immunity. In addition, a network of immune mediators plays a substantial role in the inflammatory cascade. Recently, we found that the immunopathogenesis of BU is distinct from other autoimmune uveitides regarding intraocular effector cell profiles, maturation markers of dendritic cells, and the cytokine/chemokine environment. In addition, accumulating evidence indicates the involvement of Th17 cells in BD and BU. Recent studies on genetics and biologic therapies in refractory BU also support the immunological association with the pathogenesis of BU. In this review, we provide an overview of novel findings regarding the immunopathogenesis of BU.

1. Introduction

Endogenous autoimmune uveitis comprises a clinically heterogeneous group of intraocular inflammatory diseases of various types and etiologies that can lead to blindness [1]. It is thought to be triggered by various specific and nonspecific agents in the early disease stage, but the chronicity of the inflammatory process is influenced by endogenous host factors, in which the immune system plays an important role. Although autoimmune uveitis includes a range of clinical entities (most of idiopathic origin), its immunological findings are characterized by the predominant infiltration of T cells, which implies that endogenous uveitis is a T cell-mediated autoimmune disease [2]. The development of autoimmune uveitis depends on several factors such as the nature of antigenic stimulus, subsets of competent antigen-presenting cells (APCs), increased chemotaxis of inflammatory cells, and related inflammatory mediators (e.g., chemokines and cytokines) produced by these cells.

Behçet’s disease (BD) is a chronic, recurrent systemic inflammatory disorder characterized by oral and genital mucous ulcerations, skin lesions, and uveitis. The pathogenesis of BD remains unclear, but microbial triggers, environmental factors, endothelial dysfunction, genetic predisposition, and immunological abnormalities have been implicated [3]. Behçet’s uveitis (BU) is characterized by chronic panuveitis or posterior uveitis with necrotizing retinal vasculitis and tends to be more recurrent and sight threatening than other endogenous uveitides such as Vogt-Koyanagi-Harada (VKH) disease or HLA-B27-associated uveitis. Previously, in a series of reports, we showed that immunopathogenic mechanism of BU probably differs from those of other
endogenous uveitides [4–7]. In BD patients with active uveitis, immune effectors in aqueous humor and peripheral blood differentiated the disease from endogenous uveitis of other origins [4, 5]. The intraocular cytokine environment and chemokine expressions in intraocular lymphocytes were also different between active BU and non-Behc¸et’s uveitis [6, 7]. Higher expressions of maturation markers in dendritic cells (DCs) may reflect disease activity in BU [8]. Furthermore, these factors can contribute to the chronic and recurrent nature of BU. In this paper, we review advances in the immunopathogenesis of BU with regard to antigens, immune cells and mediators, genetics, and immune therapy with biologics.

2. Antigens and Autoantigens in the Pathogenesis of Behc¸et’s Uveitis

Oral ulcers are the first symptom in about 70% of BD patients, and decrease of some disease symptoms after antibiotic treatment suggests a role of bacteria in the etiology of BD [9, 10]. In addition, the HSV-1 genome and serum antibodies against the virus have been reported in a higher proportion of patients with BD than in normal controls [9]. Moreover, the inoculation of HSV into mice was found to cause ocular inflammation mimicking BU [11]. Some bacteria such as Borrelia burgdorferi and Helicobacter have been proposed to act as triggering factors in BD, but no evidence has been presented that BD is a result of direct infection by viruses or bacteria.

It has been proposed that cross-reactivity between microbial heat shock protein (HSP) and human HSP underlies the relation between infection and autoimmunity [12] (Figure 1). Some peptides within mycobacterial 65 kDa HSP sharing significant homology with those of human mitochondrial HSP have been demonstrated to be responsible for the proliferation of γδ T cells in BD patients [13, 14]. In this regard, Direskeneli and Saruhan-Direskeneli [15] proposed a role for HSP65 as a potential T cell antigen.

T cell responses against retinal autoantigens have been demonstrated in various types of ocular inflammations such as BU. Some epitopes of S antigen were found to share homology with particular amino acid regions of HLA-B51 and HLA-B27, which suggests that this antigen contributes to the pathogenesis of BU [16, 17]. In addition, retinal tissue damage and significant increase in nitric oxide (NO) production were found in experimental models of autoimmune uveitis induced by S antigen or interphotoreceptor retinoid binding protein [18, 19].

3. Immune Cells in the Pathogenesis of Behc¸et’s Uveitis

3.1. Antigen-Specific Effector T Cells as Inducers. CD4+ T cells play an important role in immune system by orchestrating the function of other immune cells. When activated by pathogen, naïve CD4+ T cells differentiate into two different functional subsets, that is, helper T cell type 1 (Th1) and type 2 (Th2), which differ in terms of cytokine production. Th1 cells produce the cytokines interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), which activate macrophages and are responsible for cell-mediated immunity. In contrast, Th2 cells produce cytokines such as interleukin-4 (IL-4) and IL-13 which are responsible for antibody-mediated immunity by B cells [20]. Th1 and Th2 cells play important regulatory roles in the immune system [21], and Th1/Th2 imbalance may underlie the pathogenesis of several autoimmune diseases [22].

Previously, our analysis of immune cell types in active BU revealed that the predominant intraocular infiltrating cells were CD8+ T cells, whereas CD4+ T cells were the predominant infiltrating cells in patients with other uveitides [4]. In particular, in BU, the number of CD3+CD56+ cells (NKT cells) was much higher in aqueous humor than in other uveitides, and CD8+CD56+ cells were the predominant subtype among NKT cells. These unique features displayed by the cytotoxic effectors of BU may reflect the more recurrent and greater destructive nature of BU than of other uveitides. Furthermore, immune reactions evoked by certain infectious agents or by the autoantigens presented by APCs might induce the immunopathogenic hypersensitivity of cytotoxic effector cells. Additional study by our group showed that CD8brightCD56+ T cells in BU patients have a cytotoxic effector phenotype with functional NK receptor and they exert cytolytic functions against vascular endothelial cells through fasL- and perforin-dependent pathways [23]. The predominance of CD8+ T cells and NKT cells in the intraocular infiltrating cell population in active BU is in line with the unique increase in aqueous IL-15 levels. In active BU patients, intraocular IL-15 level is more elevated than in other endogenous uveitides [6, 24]. IL-15 is involved in the development and survival of immune effector cells, such as NK cells, NKT cells, and CD8+ T cells, and contributes to homeostasis and to the activation of γδ T cells [25, 26]. Thus, IL-15 is considered to participate in the selective recruitment of unique effectors in BU.

However, the mechanism underlying the hypersensitivity of T cells to various antigens has not been determined, and, presently, it is unclear whether this hypersensitivity is due to intrinsic T cell defects or whether it occurs secondary to functional abnormalities of DCs.

3.2. Roles of Dendritic Cells in Behc¸et’s Uveitis. DCs are the most potent APCs and play a crucial role in the polarization of naïve T cells into Th1 or Th2 cells [27]. DCs mature during their migration from the periphery to lymph nodes, and this process involves the upregulation of major histocompatibility complex (MHC) class II and costimulatory molecules [28–33].

We have shown that peripheral blood DC maturation profiles in patients with endogenous uveitis including BU exhibit higher expression of MHC class II and costimulatory molecules even in the absence of uveitis compared with healthy controls. This suggests that the maturation status of DCs is important in perpetuating inflammation as well as generating uveitis [8]. The relatively high expression of costimulatory molecules and MHC class II in BD patients in remission suggests that DC maturation is related to the chronicity and recurrence of uveitis. DCs may be involved in
3.3. Roles of Neutrophils in Behçet’s Uveitis. Neutrophils constitute the major component of the innate immunity system. Neutrophil hyperactivation, which can be confirmed by the upregulations of CD10, CD11a, and CD14 on cell surfaces, is believed to play an important role in the pathogenesis of BD by increasing chemotaxis, phagocytosis, superoxide generation, and myeloperoxidase levels [39–42]. Although mechanism of hyperactivation is not fully understood in BD, proinflammatory cytokines secreted by T cells or APCs such as TNF-α, IL-8, IFN-γ, or G-CSF appear to be responsible for the priming of neutrophils [43, 44]. In addition to Th1 cytokines, Th17 cytokine, IL-17, has been reported to promote neutrophil recruitment to sites of inflammation and to regulate neutrophil-associated inflammation [45, 46]. Furthermore, inflammatory cytokines produced by activated neutrophils, such as IL-18, seem to promote neutrophil activation, and in so doing they create a vicious cycle [43, 47].

Histopathological analyses of BD inflammatory lesions have shown neutrophils which represent the major cell population in vascular infiltrates [40, 48]. Furthermore, the generation of reactive oxygen species by activated neutrophils has been reported to be elevated in BD patients [49, 50].

Figure 1: Immunopathogenesis of Behçet’s uveitis. Hypersensitivity of T cells and cytotoxic cells to various antigens and predisposing genetic factors play a crucial role in the pathogenesis of Behçet’s uveitis. The high maturation profiles of dendritic cells can contribute to the perpetuation of the inflammation, and chemokines and cytokines are mediators that can generate and augment the immune response in inflammatory cascade.
and thought to be responsible for tissue damage by causing vascular endothelial cell dysfunction and thrombosis [51–53]. In recurrent uveitis attacks in BD, hypopyon consists of inflammatory cells infiltrating the eye, most of which are polymorphonuclear cells (PMNs) [54]. Fujimori et al. [39] reported fluctuations in the apoptosis level of PMNs in accord with uveitic activity in BD patients and attributed this to impairment of the FasL-Fas interaction, which the authors suggested might explain the alternation between sudden inflammation attacks and self-limiting resolution in BU. In a small case series, absorptive neutrophil apheresis in refractory ocular BD patients reduced the frequencies of ocular attacks implying that neutrophil hyperactivity plays a role in the pathogenesis of BU [55].

4. Cytokine and Chemokine Environment in Behçet’s Uveitis

Th1 immune response plays an important role during the pathogenesis of BD. Increased productions of Th1 cytokines such as IL-2, IL-12, and IFN-\(\gamma\) have been reported in the peripheral blood mononuclear cells (PBMCs) of active BD patients, while the frequency of Th2 cytokine IL-4 producing cells was decreased [56–59]. In particular, IL-12 is primarily produced by APCs and plays a crucial role in Th1 polarization. Furthermore, Th1-polarized cytokine environment rich in IL-8, IL-12, and IL-12 mRNA, TNF-\(\alpha\), and IFN-\(\gamma\) has been reported in the active inflammatory lesions of BD patients, such as skin, oral and genital mucosa, stomach, intestine, and eye [6, 22, 60–62].

Uveitis in BD can be distinguished from other causes of uveitis by its intraocular cytokine profile as well as its immune effectors. In ocular BD patients, Th1-dominant immune response is observed both in peripheral blood and in aqueous humor as in other endogenous uveitides or in other inflammatory sites of BD patients [6, 7, 24, 61]. However, Th1 polarization in BU tends to be more extreme than that observed in endogenous uveitides of other causes and shows higher proinflammatory but lower immunosuppressive cytokine profiles [6, 24]. Previously, we reported that active BU patients have higher levels of IFN-\(\gamma\) and TNF-\(\alpha\) but lower level of IL-4 than non-Behçet’s uveitis patients [6]. In addition, IL-10, the immunosuppressive regulatory T cell (T\(_{reg}\)) related cytokine, was not detected in any BU patient. IFN-\(\gamma\)-producing T cell number has been reported to be elevated in active BU patients [5, 23, 59]. CD56+ T cell subsets, including CD8\(^{bright}\)CD56+ and CD56+CD8\(^{+}\) T cells, are considered to be the cell population primarily responsible for IFN-\(\gamma\) production [5], and CD8\(^{bright}\)CD56+ T cells in active BD uveitis have been reported to be polarized to produce larger amounts of IFN-\(\gamma\) on stimulation than those in inactive BD and normal controls [23]. In active BU, IFN-\(\gamma\) levels are much higher in aqueous humor than in serum, which suggests that it is actively produced in eyes [5, 6]. A classical Th1 type cytokine IFN-\(\gamma\) exerts its cytotoxic effects by promoting cytotoxic CD8+ T cell-mediated target cell destruction and inducing NO production [63, 64]. In addition to the presumed fasL- and perforin-dependent pathways of CD8+CD56+ T cells, oxidative stresses such as those produced by NO-associated process are thought to be involved in pathogenesis of obliterating vasculitis, one of main features of ocular BD [49, 65]. In particular, the cytotoxic effects of IFN-\(\gamma\) and TNF-\(\alpha\) on vascular endothelial cells were shown to be mediated by elevated NO production [63]. BD patients with active uveitis were reported to exhibit significantly higher levels of IFN-\(\gamma\) and NO in plasma and PBMC supernatants than inactive BU patients or controls [53, 66]. Moreover, IFN-\(\gamma\) significantly increased NO production by PBMCs from BU patients in vitro whereas IL-10 decreased NO production, which suggests that IL-10 has immunoregulatory function [53].

The expression of Th1-related chemokine receptors, such as CCR5 and CXCR3, is upregulated in active BD [22, 56, 60, 62], which is consistent with our finding that CXCR3 is preferentially expressed on intraocular CD8+ T cells in BU [7]. Because CXCR3 is considered a marker of the main producers of IFN-\(\gamma\) in the T cell population, CXCR3+ T cells may be the primary effectors of the maintenance of uveitis in BD [56].

5. Novel Helper T Cell Pathways in Behçet’s Uveitis

5.1. Th17-Type Immune Response in Behçet’s Uveitis. Although BD used to be regarded as a Th1-mediated disease, accumulating evidence suggests that both Th1 and Th17 pathways contribute to its pathogenesis via the involvements of their respective proinflammatory cytokines. Furthermore, recent studies have shown that Th17 cells, a subset of T helper cells unrelated to Th1 and Th2, are implicated in many autoimmune and inflammatory diseases [51, 67, 68]. Th17 cells regulate inflammation by promoting the productions of distinct cytokines such as IL-17, IL-21, IL-22, and IL-26 [69]. Circulating Th17 cell proportion and the ability to produce IL-17, the representative Th17 cytokine, are both enhanced in active BD, and Th17 levels decrease during the remission stage versus the active stage [70, 71]. In patients with endogenous uveitis including BU, aqueous levels of IFN-\(\gamma\) and IL-17 are significantly higher than in controls, suggesting that both Th1 and Th17 cells are involved in the pathogenesis of endogenous uveitis [24]. IL-23, another Th17-associated cytokine, is a member of the IL-12 family sharing a p40 subunit with IL-12 and is believed to play an important role in the survival and maintenance of Th17 cells [72, 73].

Recent reports suggest that Th17/Th1 and Th17/T\(_{reg}\) balances are important regulators of inflammation activity in BD [51, 70, 74–77]. More specifically, patients with active BD have a significantly higher Th17/Th1 cell ratio in peripheral blood than healthy controls, and this is more prominent in patients with folliculitis or uveitis [74]. Under inflammatory conditions, T\(_{reg}\) cells can convert into Th17 cells under the influence of IL-1\(\beta\) or IL-2 [71, 78]. On the other hand, the reduction in Th17 levels during the inflammation remission stage in BD is believed to be due to the conversion of Th17 cells to T\(_{reg}\) cells [71, 79]. In one study, the stimulation of CD4+ T cells with IL-21 increased Th17 and Th1 differentiation but decreased T\(_{reg}\) cell proportions in peripheral blood, and the inhibition of IL-21 restored Th17/T\(_{reg}\) homeostasis [80].
In BD patients with active uveitis, IL-17 levels are elevated in peripheral blood or ocular fluid [24, 79, 81, 82], and it has been established that CD4+CD45RO+ (memory) T cells and γδ T cells are major sources of IL-17 [82–87]. Chi et al. [81, 82] showed that serum levels of IL-17, IL-23, and IFN-γ were significantly higher in BD patients with active uveitis than in BD patients without uveitis or healthy controls. In their study, recombinant IL-23 was found to upregulate IL-17 production [82]. In another study, Th17 cell lines from active BU patients exposed to anti-TNF-α antibody in vitro failed to produce IL-17 and showed diminished expression of the Th17 transcription factor, RORγt, suggesting that TNF-α plays a role in Th17 differentiation [79].

5.2. Th22-Type Immune Response in Behçet’s Uveitis. Recently, another novel subset of CD4+ effector Th cells (Th22) was identified which mainly produces IL-22 and TNF-α but no other T helper cell marker cytokines such as IFN-γ (Th1), IL-4 (Th2), or IL-17 (Th17) and thus is considered to be distinct from Th1, Th2, and Th17 cell types [88, 89]. Furthermore, accumulating evidence indicates that Th22 cells are involved in pathogenesis of various autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis [90–93].

IL-22 producing CD4+ cells have been reported to play a role in BD patients with active uveitis [94, 95]. Sugita et al. [94] established Th22-type T cell clones from the aqueous humor of active BU patients and found that they produced large amounts of IL-22 and TNF-α but no Th1 or Th17 cytokines. When exposed to infliximab in vitro, Th22 cells produced less Th22-related molecules, suggesting that TNF-α plays a role in Th22 differentiation in BD. In another study, it was found that IL-22 levels in the supernatants of stimulated PBMCs were higher for BD patients with active uveitis than for patients without uveitis or normal controls. In addition, IL-22 levels were found to be correlated with the severity of retinal vasculitis and anterior chamber inflammation [95].

6. Genetic Mechanisms of Susceptibility to Behçet’s Uveitis

6.1. Genetic Predisposition to Behçet’s Disease. Since the strong association between BD and HLA-B51 was found by Ohno et al. [96], many studies from different ethnic groups have confirmed their finding [97–107]. A meta-analysis of 4,800 BD patients and 16,289 controls included 78 studies that reported a pooled OR of 5.78 (95% CI 5.00–6.67) for the development of BD by HLA-B51/B55 carriers as compared with controls [108]. Furthermore, the study estimated population attributable risks of HLA-B51/B55 for BD development to be 32–52% within different geographic areas. A recent large-scale genome-wide association study (GWAS) conducted in Turkey with the largest cohort recruited to date confirmed this result with an OR of 3.49 (95% CI 2.95–4.12) [109]. Nevertheless, the role of HLA-B51 in the pathogenesis of BD remains unclear. Suggested mechanisms include the presentation of HLA-B51-restricted peptides to CD8+ T cells or interaction with NK cells, CD8+ T cells, and γδ T cells via its HLA-Bw4 epitope, but much remains to be clarified [109–113]. Recently, two large-scale GWAS indicated an association between BD and MHC class I complex near the HLA-A gene, which was suggested to be HLA-A62 by another GWAS conducted in Japan, independent of HLA-B51 [109, 114, 115]. This association has been observed in other populations [116–118].

Regarding MHC genes other than HLA-B51 and HLA-A, associations have been reported between HLA-B15 [119], HLA-B27 [120], and HLA-B5701 [121] and BD, but these associations have not been confirmed by GWAS. MIC-A (MHC class I chain-related gene A) was also considered to be responsible for BD susceptibility, because its location is just 46 kb centromeric to HLA-B [122–124]. But recent data suggest that the association between BD and MIC-A depends on the real disease susceptibility of HLA-B51, as MIC-A and HLA-B51 are in strong linkage disequilibrium [115, 125–127]. The TNF gene is located in the HLA class III region, and there have been discrepancies in the association between TNF-α promoter polymorphisms and BD [128–131]. A recent meta-analysis revealed a significant association between BD and TNF-α polymorphisms (−238A, −857T, and −1031C) [132], but GWAS failed to confirm these associations [109, 114].

Beyond the MHC, several genes encoding for cytokines, chemokines, or immunoregulatory proteins have been assessed with respect to their participations in the pathogenesis of BD, but results obtained were inconsistent [51, 133, 134]. Two recent GWAS reports from Turkey and Japan and their additional meta-analyses which included cohorts from Europe, Middle East, and Korea revealed consistent and significant associations between the IL-10 and IL-23R/IL-12RB2 genes and BD [109, 114]. In particular, the IL-10 gene variant was associated with reduced mRNA expression and IL-10 production [109]. IL-10 is a major anti-inflammatory cytokine and downregulator of Th1 immune response, and in the context of ocular inflammation, IL-10 plays a role in the development of anterior chamber-associated immune deviation via the induction of Treg cells and inhibition of Th1 response [135]. Other studies have provided evidence that promoter region polymorphisms or haplotype-tagging polymorphisms in the IL-10 gene are associated with ocular involvement of BD [136, 137]. IL-23, which shares p40 subunit with IL-12 as described above, is a proinflammatory cytokine that promotes the Th17 pathway and its association with BD implies the importance of Th17 response in BD pathogenesis.

6.2. Genetic Studies on Behçet’s Uveitis. In view of the high rate of ocular involvement in BD patients, identified genetic susceptibility factors to BD might exert their effects on the pathogenesis of uveitis in BD in the same manner. However, genetic studies solely for BD patients with uveitis could provide further understanding of the pathogenesis of BU, although there have been limited numbers of such studies. Recently, case control association studies in Chinese Han population showed that monocyte chemoattractant protein-(MCP-)1 gene and migration inhibitory factor (MIF) gene polymorphisms were associated with ocular BD [138, 139]. MCP-1, now known as CCL2, is a potent chemokine that contributes to monocyte recruitment during infection or...
After inhibiting TNF-\(\alpha\), fewer activated macrophages and PMNs were found in retina. When this recommendation was made, a number of reports provided evidence regarding the efficacy of infliximab for the treatment of BU [157–162]. A prospective comparative study showed that infliximab enabled faster and more efficient inflammation control than intravenous or intravitreal corticosteroids in BD patients with panuveitis [162]. In BD patients, a single infusion of infliximab significantly reduced the number of TNF-\(\alpha\)-secreting PBMCs within 24 hours [163]. Recently, the intravitreal use of infliximab in BU was reported to provide intraocular inflammation control without adverse effects [164].

Although the mechanism responsible for the effect of anti-TNF-\(\alpha\) agents has not been elucidated, the influence of infliximab on T cell dysregulation in BD has been investigated. CD4+ T cells obtained from peripheral blood of infliximab-treated patients with refractory uveitis including BU showed higher expression of the T\(_\text{reg}\)-specific marker Foxp3 than patients treated with colchicine or cyclosporine, suggesting the usefulness of infliximab in uveitic patients with decreased peripheral T\(_\text{reg}\) cell counts [165]. In addition, infliximab was found to suppress the in vivo and in vitro expansion and activation of \(\gamma\delta\) T cells, which have potent cytotoxic effector activity [166]. Recently, gene expression profiles in PBMCs from refractory BU patients were investigated using DNA microarray technology, and infliximab treatment was found to reduce the expression of inflammatory cytokine-related genes such as IL-2R, IFN-\(\gamma\), IL-6, IL-6R, gpl130, and IL-17R [167].

7.1. Anti-TNF-\(\alpha\) Therapy for Behc\(\ddot{e}\)et's Uveitis. TNF-\(\alpha\) is a pleiotropic cytokine that plays a major role in pathogenesis of various inflammatory disorders and autoimmune diseases such as noninfectious uveitis. TNF-\(\alpha\) exerts its proinflammatory effects by activating macrophages, facilitating CD4+ T cell development, and upregulating other cytokines, and its levels have been shown to be elevated in the serum and ocular fluid of uveitis patients, especially during the active phase [6, 152, 153]. Experimentally, lower levels of tissue damage and fewer activated macrophages and PMNs were found in retina after inhibiting TNF-\(\alpha\) [154].

Infliximab, a human–murine chimeric monoclonal antibody against TNF-\(\alpha\), was the first anti-TNF-\(\alpha\) agent used to treat BU [155]. In 2006, an expert panel on BD recommended that a single infusion of infliximab could be used as a first-line therapy to achieve rapid response in cases with posterior uveitis and significant visual impairment of less than 20/100, inflammation of the macular area, and bilateral posterior inflammation [156]. After this recommendation was made, a number of reports provided evidence regarding
Recently, rituximab has been reported to be efficient for inflammation control in intractable BU, but more evidence is needed [185,186]. On the other hand, daclizumab, an IL-2R antagonist, was not found to be effective in BU in a randomized controlled trial [190], though beneficial in other forms of noninfectious uveitis [186,187]. We lack information on the therapeutic effects of other anti-interleukin agents in BU.

CD20 is a surface antigen expressed on early to mature B cells and is another immunotherapy target molecule. Rituximab, a monoclonal anti-CD20 antibody, is an effective treatment for systemic autoimmune diseases [191], and it appears that rituximab has cytotoxic effects on B cells due to complement-mediated cell lysis or cell-mediated cytotoxicity [192]. Recently, rituximab has been reported to be efficient for inflammation control in intractable BU, but more evidence is needed [193,194].

8. Conclusion

Advances in immunological and genetic studies have broadened our understanding of the immunopathogenesis of BD, but much remains uncertain. Recent evidence shows derangement of T cell homeostasis; for example, the upregulations of the Th1 and Th17 pathways and decreased inhibitory regulation by Treg cells play key roles in the pathogenesis of BD. In particular, BD patients with active uveitis exhibit unique intraocular cytokine/chemokine environment and cytotoxic effector cell profiles, which imply that they influence the ocular manifestations characterized by recurrent and chronic inflammation. Furthermore, the favorable therapeutic effects of biologics in refractory BU and growing evidence of genetic susceptibility to BD suggest the importance of immune system in the pathogenesis of ocular BD.

Research into the immunopathogenetic processes involved in the development of BU could define critical points in the induction of ocular inflammation and open new possible means of rational therapeutic intervention as well as customized treatment in each BU patient.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] D. Wakefield and J. H. Chang, “Epidemiology of uveitis,” International Ophthalmology Clinics, vol. 45, no. 2, pp. 1-13, 2005.

[2] Y. Imai and S. Ohno, “Helper T-cell subsets in uveitis,” International Ophthalmology Clinics, vol. 42, no. 1, pp. 25-32, 2002.

[3] H. Yazici, “The lumps and bumps of Behcet’s syndrome,” Autoimmunity Reviews, vol. 3, supplement 1, pp. 553–554, 2004.

[4] H. G. Yu, D. S. Lee, J. M. Seo et al., “The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Behcet’s uveitis,” Clinical and Experimental Immunology, vol. 137, no. 2, pp. 437–443, 2004.

[5] J. K. Ahn, J. Seo, J. Yu, F. S. Oh, H. Chung, and H. G. Yu, “Down-regulation of IFN-γ-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behcet’s uveitis,” Investigative Ophthalmology and Visual Science, vol. 46, no. 7, pp. 2458–2464, 2005.

[6] J. K. Ahn, H. G. Yu, H. Chung, and Y. G. Park, “Intraocular cytokine environment in active Behcet uveitis,” American Journal of Ophthalmology, vol. 142, no. 3, pp. 429–434, 2006.

[7] T. W. Kim, H. Chung, and H. G. Yu, “Chemokine expression of intraocular lymphocytes in patients with Behcet uveitis,” Ophthalmic Research, vol. 45, no. 1, pp. 5–14, 2011.

[8] T. W. Kim, J. S. Kang, J. M. Kong et al., “Maturation profiles of peripheral blood dendritic cells in patients with endogenous uveitis,” Immunology Letters, vol. 142, no. 1-2, pp. 14–19, 2012.

[9] T. Lehner, “The role of heat shock protein, microbial and auto-immune agents in the aetiology of Behget’s disease,” International Reviews of Immunology, vol. 14, no. 1, pp. 21–32, 1997.

[10] M. Çalgünner, S. Kiraz, I. Ertelen, M. Benekli, Y. Karaarslan, and I. Çelik, “The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet’s disease: a randomized clinical trial,” Arthritis & Rheumatism, vol. 39, no. 12, pp. 2062–2065, 1996.

[11] S. Sohn, E. Lee, D. Bang, and S. Lee, “Behcet’s disease-like symptoms induced by the Herpes simplex virus in ICR mice,” European Journal of Dermatology, vol. 8, no. 1, pp. 21–23, 1998.

[12] C. C. Zouboulis and T. May, “Pathogenesis of Adhamiantades-Behcet’s disease,” Medical Microbiology and Immunology, vol. 192, no. 3, pp. 149–155, 2003.

[13] A. Hasan, F. Fortune, A. Wilson et al., “Role of γδ T cells in pathogenesis and diagnosis of Behcet’s disease,” The Lancet, vol. 347, no. 9004, pp. 789–794, 1996.

[14] S. Kaneko, N. Suzuki, N. Yamashita et al., “Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behcet’s disease (BD) in Japan,” Clinical and Experimental Immunology, vol. 108, no. 2, pp. 204–212, 1997.

[15] H. Direskeneli and G. Saruhan-Direskeneli, “The role of heat shock proteins in Behcet’s disease,” Clinical and Experimental Rheumatology, vol. 21, no. 4, supplement 30, pp. S44–S48, 2003.

[16] H. Direskeneli, “Behcet’s disease: infectious aetiology, new auto-antigens, and HLA-B51,” Annals of the Rheumatic Diseases, vol. 60, no. 11, pp. 996–1002, 2001.

[17] J. H. Yamamoto, M. Minami, G. Inaba, K. Masuda, and M. Mochizuki, “Cellular autoimmunity to retinal specific antigens in patients with Behcet’s disease,” British Journal of Ophthalmology, vol. 77, no. 9, pp. 584–589, 1993.

[18] Z. Djeraba, A. Arroul-Lammali, O. Medjeber et al., “Nitric oxide, biomarker of experimental autoimmune uveitis induced by S antigen,” Journal Francais d’Ophthalmologie, vol. 33, no. 10, pp. 693–700, 2010.

[19] A. Arroul-Lammali, Z. Djeraba, M. Belkhelfa et al., “Early involvement of nitric oxide in mechanisms of pathogenesis of experimental autoimmune uveitis induced by interphotoreceptor retinoid-binding protein (IRBP),” Journal Francais d’Ophthalmologie, vol. 35, no. 4, pp. 251–259, 2012.
imunomodulatory effect of interleukin-10,” Journal of Interferon & Cytokine Research, vol. 31, no. 9, pp. 643–651, 2011.

[54] K. Shimada, H. Yaito, and S. Shikano, “Chemotactic activity for polymorphonuclear leucocytes of the aequorin hormone in patients with Behcet’s disease,” Nihon Ganka Gakkai Zasshi, vol. 75, no. 10, pp. 2100–2105, 1971.

[55] K. Sonoda, S. Inaba, A. Ariyama, Y. Kawano, A. Sanabi, and T. Ishibashi, “Therapeutic neutrophil apheresis in patients with ocular Behcet’s disease,” Archives of Ophthalmology, vol. 123, no. 2, pp. 267–269, 2005.

[56] H. Houman, A. Hamzaoui, I. B. Ghorbal, M. Khanfir, M. Feki, and K. Hamzaoui, “Abnormal expression of chemokine receptors in Behcet’s disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations,” Journal of Autoimmunity, vol. 23, no. 3, pp. 267–273, 2004.

[57] M. A. Frassanito, R. Dammacco, P. Cafforio, and F. Dammacco, “Th1 polarization of the immune response in Behcet’s disease: a putative pathogenetic role of interleukin-12,” Arthritis & Rheumatology, vol. 42, no. 9, pp. 1967–1974, 1999.

[58] S. Koarada, Y. Haruta, Y. Tada et al., “Increased entry of CD4+ T cells into the Th1 cytokine effector pathway during T-cell division following stimulation in Behcet’s disease,” Rheumatology, vol. 43, no. 7, pp. 843–851, 2004.

[59] N. Sugi-Ikai, M. Nakazawa, S. Nakamura, S. Ohno, and M. Minami, “Increased frequencies of interleukin-2- and interferon-γ-producing T cells in patients with active Behcet’s disease,” Investigative Ophthalmology and Visual Science, vol. 39, no. 6, pp. 996–1004, 1998.

[60] Y. Imamura, M. S. Kurokawa, H. Yoshikawa et al., “Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet’s disease,” Clinical and Experimental Immunology, vol. 139, no. 2, pp. 371–378, 2005.

[61] F. Ilhan, T. Demir, P. T¨urkc¸uoˇg l u , B. Turgut, N. Demir, and A. Gödekermerdin, “Th1 polarization of the immune response in uveitis in Behcet’s disease,” Canadian Journal of Ophthalmology, vol. 43, no. 1, pp. 105–108, 2008.

[62] A. M. Dalghous, J. Freysdottir, and F. Fortune, “Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet’s disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD,” Scandinavian Journal of Rheumatology, vol. 35, no. 6, pp. 472–475, 2006.

[63] J. Yamaoka, K. Kabashima, M. Kawanishi, K. Toda, and Y. Miyachi, “Cytotoxicity of IFN-γ and TNF-α for vascular endothelial cell is mediated by nitric oxide,” Biochemical and Biophysical Research Communications, vol. 291, no. 4, pp. 780–786, 2002.

[64] E. Roth and H. Pircher, “IFN-γ promotes fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T Cells,” The Journal of Immunology, vol. 172, no. 3, pp. 1588–1594, 2004.

[65] S. Buldanlioglu, S. Turkmen, H. B. Ayabakan et al., “Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behcet’s disease,” British Journal of Dermatology, vol. 153, no. 3, pp. 526–530, 2005.

[66] F. Djaballah-Ider, S. Chaib, H. Belguendouz, D. Talbi, and C. Touil-Boukouffa, “T cells activation and interferon-γ/nitric oxide production during Behcet disease: a study in Algerian patients,” Ocular Immunology and Inflammation, vol. 20, no. 3, pp. 215–217, 2012.

[67] S. Brand, “Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease,” Gat, vol. 58, no. 8, pp. 1152–1167, 2009.

[68] H. H. Wang, Y. Q. Dai, W. Qiu et al., “Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse,” Journal of Clinical Neuroscience, vol. 18, no. 10, pp. 1313–1317, 2011.

[69] C. Dong, “Th17 cells in development: an updated view of their molecular identity and genetic programming,” Nature Reviews Immunology, vol. 8, no. 5, pp. 337–348, 2008.

[70] K. Hamzaoui, “Th17 cells in Behcet’s disease: a new immunoregulatory axis,” Clinical and Experimental Rheumatology, vol. 29, supplement 67, no. 4, pp. S71–S76, 2011.

[71] K. Hamzaoui, E. Bouali, I. Ghorbel, M. Houman, and A. Hamzaoui, “Expression of Th-17 and RORgammat mRNA in Behcet’s disease,” Medical Science Monitor, vol. 17, no. 4, pp. CR227–CR234, 2011.

[72] N. Qu, M. Xu, I. Mizoguchi et al., “Pivotal roles of Th17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases,” Clinical and Developmental Immunology, vol. 2013, Article ID 968549, 13 pages, 2013.

[73] C. L. Langrish, Y. Chen, W. M. Blumenschein et al., “IL-23 drives a pathogenic T cell population that induces autoimmune inflammation,” Journal of Experimental Medicine, vol. 201, no. 2, pp. 233–240, 2005.

[74] J. Kim, J. A. Park, and E. Y. Lee, “Imbalance of Th17 to Th1 cells in Behcet’s disease,” Clinical and Experimental Rheumatology, vol. 28, supplement 60, no. 4, pp. S16–S19, 2010.

[75] A. Cruz, S. A. Khader, E. Torrado et al., “Cutting edge: IFN-γ regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection,” Journal of Immunology, vol. 177, no. 3, pp. 1416–1420, 2006.

[76] K. Hamzaoui, A. Borhani Haghghi, I. B. Ghorbel, and H. Houman, “RORC and Foxp3 axis in cerebrospinal fluid of patients with Neuro-Behcet’s Disease,” Journal of Neuroimmunology, vol. 233, no. 1-2, pp. 249–253, 2011.

[77] L. Zhou, J. E. Lopes, M. M. W. Chong et al., “TGF-B-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function,” Nature, vol. 453, no. 7192, pp. 236–240, 2008.

[78] I. Kryczek, S. Wei, L. Vatan et al., “Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression,” Journal of Immunology, vol. 179, no. 3, pp. 1423–1426, 2007.

[79] S. Sugita, Y. Kawazoe, A. Imai, Y. Yamada, S. Horie, and M. Mochizuki, “Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behcet’s disease,” Arthritis Research and Therapy, vol. 14, no. 3, article R99, 2012.

[80] G. Geri, B. Terrier, M. Rosenzwajg et al., “Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease,” Journal of Allergy and Clinical Immunology, vol. 128, no. 3, pp. 655–664, 2011.

[81] W. Chi, P. Yang, X. Zhu et al., “Production of interleukin-17 in Behcet’s disease is inhibited by cyclosporin A,” Molecular Vision, vol. 16, pp. 880–886, 2010.

[82] W. Chi, X. Zhu, P. Yang et al., “Upregulated IL-23 and IL-17 in Behcet patients with active uveitis,” Investigative Ophthalmology and Visual Science, vol. 49, no. 7, pp. 3058–3064, 2008.

[83] J. Shimizu, K. Takai, N. Fujii et al., “Excessive CD4+ T cells co-expressing interleukin-17 and interferon-γ in patients with Behcet’s disease,” Clinical and Experimental Immunology, vol. 168, no. 1, pp. 68–74, 2012.

[84] H. C. K. Shin, N. Benbernou, S. Esnault, and M. Guenounou, “Expression of IL-17 in human memory CD45RO+ T lymphocytes and its regulation by protein kinase A pathway,” Cytokine, vol. 11, no. 4, pp. 257–266, 1999.
A.Gül, F.A. Uyar, M.Inanc, et al., "A weak association of HLA-
N. Mizuki, M. Ota, Y. Katsuyama et al., "Association analysis
M. Yang, T.Y. Lai, F.O. Luk, and C.P. Pang, "The roles of genetic factors in uveitis and their clinical significance," Retina,
H. Ghasemi, T. Ghazanfari, R. Yaraee, P. Owlia, Z. M. Hassan,
G. Wallace and D.H. Vertity, L.J. Delamain et al., "The role sof
T. Arayssi, A.R. Hamdan, Z. Touma et al., "TNF polymorph-
G. Wallace and E. Niemczyk, "Genetics in ocular inflamm-
E. Hughes, R.W. M. Collins, E. Kondeatis et al., "Associations of major histocompatibility complex class I-chained molecules polymorphisms with Behçet’s disease in Causcasian patients," Tissue Antigens, vol. 66, no. 3, pp. 195–199, 2005.
M. Piga and A. Mathieu, "GeneticsusceptibilitytoBehc¸et'sdis-
H. Ghasemi, T. Ghazanfari, R. Yaraee, P. Owlia, Z. M. Hassan,
G. Wallace and E. Kondeatis, R. W. Vaughan et al., "IL-10 genotype analysis in patients with Behçet’s disease," Human
M. Ota, N. Mizuki, Y. Katsuyama et al., "The critical region for Behçet disease in the human major histocompatibility complex is reduced to a 46-kb segment centromeric of HLA-B, by association analysis using refined microsatellite mapping," American Journal of Human Genetics, vol. 64, no. 5, pp. 1406–1410, 1999.
G. Wallace, D.H. Verity, L.J. Delamain et al., "MIC-A allele profiles and HLA class I associations in Behçet’s disease," Immunogenetics, vol. 49, no. 7-8, pp. 613–617, 1999.
M. L. C. Marin, C. R. Savioli, I. H. Yamamoto, J. Kail, and A. C. Goldberg, "MIC-A polymorphism in a sample of the São Paulo population, Brazil," European Journal of Immunogenetics, vol. 31, no. 2, pp. 63–71, 2004.
N. Mizuki, M. Ota, Y. Katsuyama et al., "Association analysis between the MIC-A and HLA-B alleles in Japanese patients with Behçet’s disease," Arthritis & Rheumatism, vol. 42, no. 9, pp. 1961–1966, 1999.
E.H. Hughes, R.W. M. Collins, E. Kondeatis et al., "Associations of major histocompatibility complex class I-chained molecule polymorphisms with Behçet’s disease in Causcasian patients," Tissue Antigens, vol. 66, no. 3, pp. 195–199, 2005.
M. Piga and A. Mathieu, "Genetic susceptibility to Behçet’s disease: role of genes belonging to the MHC region," Rheumatology, vol. 50, no. 2, Article ID keq331, pp. 299–310, 2011.
K. Park, N. Kim, J. Nam, D. Bang, and E. Lee, "Association of TNFA promoter region haplotype in Behçet’s disease," Journal of Korean Medical Science, vol. 21, no. 4, pp. 596–601, 2006.
T.K. Arayassi, A.R. Hamdan, Z. Touma et al., "TNF polymorph-
isms in Lebanese patients with Behçet’s disease," Clinical and Experimental Rheumatology, vol. 26, no. 4, supplement 50, pp. S130–S131, 2008.
A. Akman, N. Sallakci, M. Coskun et al., "TNF-α gene 1031 T/C polymorphism in Turkish patients with Behçet’s disease," British Journal of Dermatology, vol. 155, no. 2, pp. 350–356, 2006.
Z. Touma, C. Farra, A. Hamdan et al., "TNF polymorphisms in patients with Behçet disease: a meta-analysis," Archives of Medical Research, vol. 41, no. 2, pp. 142–146, 2010.
G. Wallace and E. Niemczyk, "Genetics in ocular inflammation-basic principles," Ocular Immunology and Inflammation, vol. 19, no. 1, pp. 10–18, 2011.
M. M. Yang, T. Y. Lai, F. O. Luk, and C. P. Pang, "The roles of genetic factors in uveitis and their clinical significance," Retina, vol. 34, no. 1, pp. 1–11, 2014.
H. Ghasemi, T. Ghazanfari, R. Yaraee, P. Owlia, Z. M. Hassan, and S. Faghhiзадeh, "Roles of IL-10 in ocular inflammations: a review," Ocular Immunology and Inflammation, vol. 20, no. 6, pp. 406–418, 2012.
D. Atan, S. Fraser-Bell, and J. Plskova, "Cytokine polymorphism in noninfectious uveitis," Investigative Ophthalmology & Visual Science, vol. 51, no. 8, pp. 4133–4142, 2010.
G. Wallace, E. Kondeatis, R. W. Vaughan et al., "IL-10 genotype analysis in patients with Behçet’s disease," Human Immunology, vol. 68, no. 2, pp. 122–127, 2007.
S. Hou, P. Yang, L. Du et al., "Monocyte chemotactic protein-1-2518 A/G single nucleotide polymorphism in Chinese Han patients with ocular Behçet’s disease," Human Immunology, vol. 71, no. 1, pp. 79–82, 2010.
X. Zheng, D. Wang, S. Hou et al., "Association of macrophage migration inhibitory factor gene polymorphisms with Behçet’s disease in a Han Chinese population," Ophthalmology, vol. 119, no. 12, pp. 2514–2518, 2012.
A. Yadav, V. Saini, and S. Arora, "MCP-1: chemotactractor with a role beyond immunity: a review," Clinica Chimica Acta, vol. 411, no. 21-22, pp. 1570–1579, 2010.
T. Calandra and T. Roger, "Macrophage migration inhibitory factor: a regulator of innate immunity," Nature Reviews Immunology, vol. 3, no. 10, pp. 791–800, 2003.
M. Cho, J. Kim, H. Ko et al., "The MCP-1 promoter - 2518 polymorphism in Behçet’s disease: correlation between allele types, MCP-1 production and clinical symptoms among Korean patients," Autoimmunity, vol. 37, no. 1, pp. 77–80, 2004.
N. Kitaichi, S. Kotake, Y. Sasamoto et al., "Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis," Investigative Ophthalmology and Visual Science, vol. 40, no. 1, pp. 247–250, 1999.
L. Lu and A. Liston, "MicroRNA in the immune system, microRNA as an immune system," Immunology, vol. 127, no. 3, pp. 291–298, 2009.
K. D. Taganov, M. P. Boldin, K. Chang, and D. Baltimore, "NF-
Kitaichi, S. Kotake, Y. Sasamoto et al., "Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis," Investigative Ophthalmology and Visual Science, vol. 40, no. 1, pp. 247–250, 1999.
L. Lu and A. Liston, "MicroRNA in the immune system, microRNA as an immune system," Immunology, vol. 127, no. 3, pp. 291–298, 2009.
K. D. Taganov, M. P. Boldin, K. Chang, and D. Baltimore, "NF-
Kitaichi, S. Kotake, Y. Sasamoto et al., "Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis," Investigative Ophthalmology and Visual Science, vol. 40, no. 1, pp. 247–250, 1999.
L. Lu and A. Liston, "MicroRNA in the immune system, microRNA as an immune system," Immunology, vol. 127, no. 3, pp. 291–298, 2009.
K. D. Taganov, M. P. Boldin, K. Chang, and D. Baltimore, "NF-
Kitaichi, S. Kotake, Y. Sasamoto et al., "Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis," Investigative Ophthalmology and Visual Science, vol. 40, no. 1, pp. 247–250, 1999.
L. Lu and A. Liston, "MicroRNA in the immune system, microRNA as an immune system," Immunology, vol. 127, no. 3, pp. 291–298, 2009.
K. D. Taganov, M. P. Boldin, K. Chang, and D. Baltimore, "NF-
Kitaichi, S. Kotake, Y. Sasamoto et al., "Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis," Investigative Ophthalmology and Visual Science, vol. 40, no. 1, pp. 247–250, 1999.
L. Lu and A. Liston, "MicroRNA in the immune system, microRNA as an immune system," Immunology, vol. 127, no. 3, pp. 291–298, 2009.
[152] K. Hamzaoui, A. Hamzaoui, F. Guemira, M. Bessioud, M. Hamza, and K. Ayed, "Cytokine profile in Behcêt's disease patients: relationship with disease activity," Scandinavian Journal of Rheumatology, vol. 31, no. 4, pp. 205–210, 2002.

[153] V. Pérez-Guijo, M. Santos-Lacomba, M. Sánchez-Hernández, M. D. C. Castro-Villegas, J. M. Gallardo-Galera, and E. Collantes-Estévez, "Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27," Current Medical Research and Opinion, vol. 20, no. 2, pp. 155–157, 2004.

[154] A. D. Dick, P. G. McMenamin, H. Körner et al., "Inhibition of tumour necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina," European Journal of Immunology, vol. 26, no. 5, pp. 1018–1025, 1996.

[155] P. P. Sfikakis, P. G. Theodossiadis, C. G. Katsiari, P. Kakkamanis, and N. N. Markomichelakis, "Effect of infliximab on sight-threatening panuveitis in Behcét's disease," The Lancet, vol. 358, no. 9278, pp. 295–296, 2001.

[156] P. P. Sfikakis, N. Markomichelakis, E. Alpsoy et al., "Anti-TNF therapy in the management of Behcet’s disease—review and basis for recommendations," Rheumatology, vol. 46, no. 5, pp. 736–741, 2007.

[157] I. Tugal-Tutkun, A. Mudun, M. Urgancioglu et al., "Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial," Arthritis and Rheumatism, vol. 52, no. 8, pp. 2478–2484, 2005.

[158] Y. Yamada, S. Sugita, H. Tanaka, K. Kamo, T. Kawaguchi, and M. Mochizuki, "Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease," British Journal of Ophthalmology, vol. 94, no. 3, pp. 284–288, 2010.

[159] A. Arida, K. Fragjidakis, E. Giavri, and P. P. Sfikakis, "Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients," Seminars in Arthritis and Rheumatism, vol. 41, no. 1, pp. 61–70, 2011.

[160] A. A. Okada, H. Goto, S. Ohno, and M. Mochizuki, "Multicenter study of infliximab for refractory uveoretinitis in Behcet disease," Archives of Ophthalmology, vol. 130, no. 5, pp. 592–598, 2012.

[161] T. Handa, H. Tsunekawa, M. Yoneda et al., "Long-term remission of ocular and extraocular manifestations in Behcet's disease using infliximab," Clinical and Experimental Rheumatology, vol. 29, no. 4, supplement 67, pp. S58–S63, 2011.

[162] N. Markomichelakis, E. Delicha, S. Masselos, K. Fragjidakis, P. Kakkamanis, and P. P. Sfikakis, "A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet's disease: a comparative 4-week study," Rheumatology, vol. 50, no. 3, pp. 593–597, 2011.

[163] A. G. Commodaro, V. Bueno, R. Belfort, and L. V. Rizzo, "Autoimmune uveitis: the associated proinflammatory molecules and the search for immunoregulation," Autoimmunity Reviews, vol. 10, no. 4, pp. 205–209, 2011.

[164] N. Markomichelakis, E. Delicha, S. Masselos, and P. P. Sfikakis, "Intravitreal infliximab for sight-threatening relapsing uveitis in Behcet's disease: a pilot study in 15 patients," The American Journal of Ophthalmology, vol. 154, no. 3, pp. 534.e1–541.e1, 2012.

[165] S. Sugita, Y. Yamada, S. Kaneko, S. Horie, and M. Mochizuki, "Induction of regulatory T cells by infliximab in Behcet's disease," Investigative Ophthalmology & Visual Science, vol. 52, no. 1, pp. 476–484, 2011.

[166] G. Triolo, A. Accardo-Palumbo, F. Dieli et al., "Vgamma9/Vdelta2 T lymphocytes in Italian patients with Behcet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease.,” Arthritis Research & Therapy, vol. 5, no. 5, pp. R262–268, 2003.

[167] H. Keino, T. Watanabe, W. Taki, and A. A. Okada, "Effect of infliximab on gene expression profiling in Behcet's disease," Investigative Ophthalmology & Visual Science, vol. 52, no. 10, pp. 7671–7686, 2011.

[168] A. N. Theoflopoulos, R. Baccala, B. Beutler, and D. H. Kono, "Type I interferons (α/β) in immunity and autoimmunity," Annual Review of Immunology, vol. 23, pp. 307–36, 2005.

[169] J. Plskova, K. Greiner, E. Muckersie, L. Duncan, and J. V. Forrester, "Interferon-α: a key factor in autoimmune disease?" Investigative Ophthalmology and Visual Science, vol. 47, no. 9, pp. 3946–3950, 2006.

[170] F. N. Yalçındağ and A. Uzun, “Results of interferon alpha-2a therapy in patients with Behcet’s disease,” Journal of Ocular Pharmacology and Therapeutics, vol. 28, no. 4, pp. 439–443, 2012.

[171] S. Onal, H. Kazokoglu, A. Koc et al., “Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis,” Archives of Ophthalmology, vol. 129, no. 3, pp. 288–294, 2011.

[172] G. Sobac, Ü. Erdem, A. H. Durukan et al., “Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments,” Ophthalmology, vol. 117, no. 7, pp. 1430–1435, 2010.

[173] L. Krause, A. Altenburg, U. Pleyer, A. Köhler, C. C. Zouboulis, and M. H. Foerster, “Long-term visual prognosis of patients with ocular Adamantani-Behect's disease treated with interferon-α-2a,” Journal of Rheumatology, vol. 35, no. 5, pp. 896–903, 2008.

[174] C. M. E. Deuter, M. Zierhut, A. Möhle, R. Vonthein, N. Stübiger, and I. Kötter, “Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behcet’s disease,” Arthritis and Rheumatism, vol. 62, no. 9, pp. 2796–2805, 2010.

[175] I. Kötter, M. Zierhut, A. K. Eckstein et al., “Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis,” British Journal of Ophthalmology, vol. 87, no. 4, pp. 423–431, 2003.

[176] I. Tugal-Tutkun, E. Güney-Tefekli, and M. Urgancioglu, “Results of interferon-alpha therapy in patients with Behcet uveitis,” Graefes Archive for Clinical and Experimental Ophthalmology, vol. 244, no. 12, pp. 1692–1695, 2006.

[177] B. Bodaghi, G. Gendron, B. Wechsler et al., “Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients,” British Journal of Ophthalmology, vol. 91, no. 3, pp. 335–339, 2007.

[178] J. Gueudry, B. Wechsler, C. Terrada et al., “Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease,” American Journal of Ophthalmology, vol. 146, no. 6, pp. 837.e1–844.e1, 2008.

[179] M. Chawla-Sarkar, D. J. Lindner, Y.-F. Liue et al., “Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis,” Apoptosis, vol. 8, no. 3, pp. 237–249, 2003.

[180] M. Treusch, R. Vonthein, M. Baur et al., “Influence of human recombinant interferon-α-2a (rhIFN-α-2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease,” Rheumatology, vol. 43, no. 10, pp. 1275–1282, 2004.

[181] A. A. Vandenbark, J. Huan, M. Agotsch et al., “Interferon-beta-1a treatment increases CD56bright natural killer cells..."
and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis,” *Journal of Neuroimmunology*, vol. 215, no. 1-2, pp. 125–128, 2009.

[182] I. Köttter, S. Koch, R. Vonthein et al., “Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet’s disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature,” *Clinical and Experimental Rheumatology*, vol. 23, no. 4, supplement 38, pp. S20–S26, 2005.

[183] S. S. Karti, E. Ovali, S. Ratip et al., “Effect of interferon-α2a on neutrophil adhesion and phagocytosis in chronic myeloid leukemia and Behçet’s disease,” *Clinical Rheumatology*, vol. 21, no. 3, pp. 211–214, 2002.

[184] S. C. B. Teoh, S. Sharma, A. Hogan, R. Lee, A. V. Ramanan, and A. D. Dick, “Tailoring biological treatment: Anakinra treatment of posterior uveitis associated with the CINCA syndrome,” *The British Journal of Ophthalmology*, vol. 91, no. 2, pp. 263–264, 2007.

[185] A. Gül, I. Tugal-Tutkun, C. A. Dinarello et al., “Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet’s disease: an open-label pilot study,” *Annals of the Rheumatic Diseases*, vol. 71, no. 4, pp. 563–566, 2012.

[186] G. N. Papaliodis, D. Chu, and C. S. Foster, “Treatment of ocular inflammatory disorders with daclizumab,” *Ophthalmology*, vol. 110, no. 4, pp. 786–789, 2003.

[187] R. B. Nussenblatt, E. Fortin, R. Schiffman et al., “Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 13, pp. 7462–7466, 1999.

[188] A. Muselier, P. Bielefeld, S. Bidot, J. Vinit, J. Besancenot, and A. Bron, “Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis,” *Ocular Immunology and Inflammation*, vol. 19, no. 5, pp. 382–383, 2011.

[189] W. Hueber, D. D. Patel, T. Dryja et al., “Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis,” *Science Translational Medicine*, vol. 2, no. 52, Article ID 52ra72, 2010.

[190] R. R. Buggage, G. Levy-Clarke, H. N. Sen et al., “A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet’s disease,” *Ocular Immunology and Inflammation*, vol. 15, no. 2, pp. 63–70, 2007.

[191] Z. Rosman, Y. Shoenfeld, and G. Zandman-Goddard, “Biologic therapy for autoimmune diseases: an update,” *BMC Medicine*, vol. 11, no. 1, article 88, 2013.

[192] R. P. Taylor and M. A. Lindorfer, “Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies,” *Current Opinion in Immunology*, vol. 20, no. 4, pp. 444–449, 2008.

[193] S. Sadreddini, H. Noshad, M. Molaeefard, and R. Noshad, “Treatment of retinal vasculitis in Behçet’s disease with rituximab,” *Modern Rheumatology*, vol. 18, no. 3, pp. 306–308, 2008.

[194] F. Davatchi, H. Shams, M. Rezaipoor et al., “Rituximab in intractable ocular lesions of Behçet’s disease; randomized single-blind control study (pilot study),” *International Journal of Rheumatic Diseases*, vol. 13, no. 3, pp. 246–252, 2010.